LEAN reports the first GLP-1 liver histology signal

A phase 2 trial called LEAN, published in 2015, gave the first evidence that a GLP-1 drug could reverse non-alcoholic steatohepatitis, or NASH, a form of liver scarring linked to obesity and diabetes. The trial found that 39% of patients on liraglutide had their NASH resolve, compared with 9% on placebo ^[1]. Fewer patients on the drug also saw their liver scarring, called fibrosis, get worse ^[1].

The study was small and short. Researchers at four UK medical centers enrolled 52 overweight adults with biopsy-confirmed NASH between August 2010 and May 2013 ^[1]. Half received daily injections of liraglutide at 1.8 mg, the same dose sold today as Saxenda for weight management, and half got placebo, for 48 weeks ^[1]. Of the 45 patients who completed treatment and had a follow-up liver biopsy, 9 of 23 on liraglutide saw their NASH resolve versus 2 of 22 on placebo, a nearly 4.3-times higher rate that the study authors called statistically significant ^[1]. Liver scarring got worse in 2 of 23 liraglutide patients compared with 8 of 22 on placebo ^[1].

Side effects were common but mostly mild. Gastrointestinal problems affected 81% of the liraglutide group versus 65% of the placebo group, including diarrhea (38% vs 19%), constipation (27% vs 0%), and loss of appetite (31% vs 8%) ^[1]. The trial's authors, whose work was funded partly by Novo Nordisk, the maker of liraglutide, concluded the drug was safe and well tolerated, and said the results justified larger, longer studies ^[1].

Despite these results, liraglutide never received FDA approval specifically for liver disease. It is approved in the US as Victoza for type 2 diabetes and as Saxenda for chronic weight management, but not as a treatment for NASH or liver fibrosis. A commentary published alongside the original trial noted it opened a new research direction rather than settling the question, and later published letters raised questions and clarifications about the study's design and reporting ^[1].

Why it matters for patients

For people already living with fatty liver disease, this 2015 trial is part of the reason later GLP-1 drugs have been studied for liver health, not just diabetes or weight. But it is important to understand what the LEAN trial did and did not show. It was a small study, with only 45 patients completing biopsies, run over less than a year ^[1]. It does not mean liraglutide is approved to treat liver disease in the US, and patients should not assume any GLP-1 drug carries a liver indication based on this early study.

The finding also does not directly apply to newer drugs like semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), or orforglipron (Foundayo). Those drugs work on similar biology but were tested separately, and the sources here do not include their liver-specific trial results.

What happens next

The sources provided do not describe specific follow-up trials or regulatory decisions after 2015. What is documented is that the LEAN results, published in the Lancet, triggered scientific commentary and debate among researchers, including published letters raising questions about the trial from other clinicians ^[1]. Whether any GLP-1 drug will eventually gain a formal liver disease indication in the US is not addressed in these sources and remains an open question.